Celcuity’s REVTORPYK Launch Builds Momentum as Competition and Regulation Loom
Celcuity says REVTORPYK is off to a strong early start, but regulatory complexity, competition and infrastructure needs remain key execution tests.
Alvotech Enters Pivotal Quarter With Three FDA Biosimilar Decisions Ahead
Alvotech faces three anticipated FDA decisions in the fourth quarter, creating a pivotal test for its commercial outlook and risk profile.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Wall Street Slides as Inflation Data Revives 50-Basis-Point Fed Hike Fears
Hotter inflation and a hawkish Federal Reserve reset rate expectations, while sharply higher mortgage rates added pressu…
Capricor Therapeutics Shares Rise Ahead of Nov. 22 FDA Decision
CAPR shares are drawing speculative interest ahead of the FDA’s Nov. 22 decision, creating a binary catalyst for traders…
Gossamer Bio Price Target Cut as Analysts Diverge on NDA Outlook
Wedbush lowered its Gossamer Bio price target over regulatory uncertainty, while H.C. Wainwright and Chardan remain bull…
GFL Environmental Plunges After Rejecting $52 Offer and Ending Sale Review
GFL Environmental shares plunged after the company rejected a $52 offer and ended its strategic review without a sale.
Hot October CPI Report Sends Stocks Lower as Markets Price In Another Fed Hike
Hotter October inflation pushed US stocks lower, lifted Treasury yields and the dollar, and strengthened expectations fo…
IsoEnergy Raises Premier American Uranium Stake to 22% as Sector Consolidation Continues
IsoEnergy’s move to raise its Premier American Uranium stake to 22% highlights consolidation and strategic positioning a…
GFL Environmental Shares Slide After Board Rejects C$52 Buyout Offer
GFL Environmental ended its strategic review without a sale after rejecting a $52-per-share private-equity offer, removi…
AstraZeneca’s Omniose Acquisition Signals Continued Appetite for Preclinical Biotech Deals
AstraZeneca’s acquisition of Omniose highlights its pipeline-building strategy and the pharmaceutical sector’s continued…
Zura Bio Plunges 76% After Tibulizumab Fails Phase 2 Hidradenitis Trial
Zura Bio shares plunged 76% after tibulizumab failed a Phase 2 hidradenitis trial, prompting the company to discontinue …